The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
Biljana Ivanovska Adjievska,1 Salih Boskurt,1 Nikola Orovcanec,2 Vesna Dimovska-Jordanova3 1Department for Posterior Segment, European Eye Hospital, Skopje, Republic of Macedonia; 2Department for Medical Statistics, Institute for Epidemiology and Medical Statistics, Medical Faculty, Skopje, Republi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-06-01
|
| Series: | Clinical Ophthalmology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/the-outcome-of-low-frequency-intravitreal-bevacizumab-therapy-for-macu-peer-reviewed-article-OPTH |
| _version_ | 1823972224684523520 |
|---|---|
| author | Ivanovska Adjievska B Boskurt S Orovcanec N Dimovska-Jordanova V |
| author_facet | Ivanovska Adjievska B Boskurt S Orovcanec N Dimovska-Jordanova V |
| author_sort | Ivanovska Adjievska B |
| collection | DOAJ |
| description | Biljana Ivanovska Adjievska,1 Salih Boskurt,1 Nikola Orovcanec,2 Vesna Dimovska-Jordanova3 1Department for Posterior Segment, European Eye Hospital, Skopje, Republic of Macedonia; 2Department for Medical Statistics, Institute for Epidemiology and Medical Statistics, Medical Faculty, Skopje, Republic of Macedonia; 3Department for Retinal Diseases, University Clinic for Eyes Diseases, St Cyril and Methodius University, Skopje, Republic of Macedonia Aim: We aimed to evaluate the 1-year efficacy and safety of low-frequency intravitreal bevacizumab in the treatment of macular edema due to retinal vein occlusions (RVOs).Methods: The study comprised an interventional prospective study of patients with macular edema due to central retinal vein occlusion (CRVO) or branch retinal vein occlusion, followed for 12 months. Treatment-naïve patients with reduced best-corrected visual acuity (BCVA) and central macular thickness (CMT) of at least 250 µm received intravitreal injection of bevacizumab. After 1 month, BCVA and optical coherence tomography (OCT) images of the macula were recorded. In patients with <30% improvement in BCVA and CMT, two more injections were applied at 1.5-month intervals. In all other patients, further injections were applied as needed. In cases with ischemic areas of retina, laser photocoagulation of the retina was performed.Results: In total, 33 patients with CRVO and 55 with BRVO were treated. After 1 year, 65 eyes (73.86%) had clinically significant improvement of BCVA (>0.3 log of the minimum angle of resolution [logMAR] units) with average number of injections of 1.98. Improvement of mean BCVA in CRVO was significant (P=0.001) from baseline (1.2±0.95 logMAR units) to 1 year (0.75±0.6 logMAR units). Significant improvement of mean BCVA (P<0.001) was also found in BRVO, from 0.71±0.75 logMAR units at baseline to 0.28±0.5 logMAR units at 1 year. Baseline CMT was 852.21±298.20 µm for CRVO and 597.95±185.63 µm for BRVO. In both groups, there was significant decrease (P<0.001) in CMT after 1 year of treatment. Panretinal laser photocoagulation was done in 75.8% of all eyes with CRVO and sectoral photocoagulation in 49.1% of eyes with BRVO.Conclusion: In macular edema due to RVO, intravitreal bevacizumab provides improvement in visual acuity and reduction of macular edema in a high percentage of treated eyes after 1 year, even with low number of injections. Keywords: macular edema, retinal vein occlusion, bevacizumab, intravitreal injection |
| first_indexed | 2024-12-18T03:38:31Z |
| format | Article |
| id | doaj.art-db43b4bbbfaf421a95e620030c416afa |
| institution | Directory Open Access Journal |
| issn | 1177-5483 |
| language | English |
| last_indexed | 2024-12-18T03:38:31Z |
| publishDate | 2017-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Ophthalmology |
| spelling | doaj.art-db43b4bbbfaf421a95e620030c416afa2022-12-21T21:22:16ZengDove Medical PressClinical Ophthalmology1177-54832017-06-01Volume 111183119033388The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusionsIvanovska Adjievska BBoskurt SOrovcanec NDimovska-Jordanova VBiljana Ivanovska Adjievska,1 Salih Boskurt,1 Nikola Orovcanec,2 Vesna Dimovska-Jordanova3 1Department for Posterior Segment, European Eye Hospital, Skopje, Republic of Macedonia; 2Department for Medical Statistics, Institute for Epidemiology and Medical Statistics, Medical Faculty, Skopje, Republic of Macedonia; 3Department for Retinal Diseases, University Clinic for Eyes Diseases, St Cyril and Methodius University, Skopje, Republic of Macedonia Aim: We aimed to evaluate the 1-year efficacy and safety of low-frequency intravitreal bevacizumab in the treatment of macular edema due to retinal vein occlusions (RVOs).Methods: The study comprised an interventional prospective study of patients with macular edema due to central retinal vein occlusion (CRVO) or branch retinal vein occlusion, followed for 12 months. Treatment-naïve patients with reduced best-corrected visual acuity (BCVA) and central macular thickness (CMT) of at least 250 µm received intravitreal injection of bevacizumab. After 1 month, BCVA and optical coherence tomography (OCT) images of the macula were recorded. In patients with <30% improvement in BCVA and CMT, two more injections were applied at 1.5-month intervals. In all other patients, further injections were applied as needed. In cases with ischemic areas of retina, laser photocoagulation of the retina was performed.Results: In total, 33 patients with CRVO and 55 with BRVO were treated. After 1 year, 65 eyes (73.86%) had clinically significant improvement of BCVA (>0.3 log of the minimum angle of resolution [logMAR] units) with average number of injections of 1.98. Improvement of mean BCVA in CRVO was significant (P=0.001) from baseline (1.2±0.95 logMAR units) to 1 year (0.75±0.6 logMAR units). Significant improvement of mean BCVA (P<0.001) was also found in BRVO, from 0.71±0.75 logMAR units at baseline to 0.28±0.5 logMAR units at 1 year. Baseline CMT was 852.21±298.20 µm for CRVO and 597.95±185.63 µm for BRVO. In both groups, there was significant decrease (P<0.001) in CMT after 1 year of treatment. Panretinal laser photocoagulation was done in 75.8% of all eyes with CRVO and sectoral photocoagulation in 49.1% of eyes with BRVO.Conclusion: In macular edema due to RVO, intravitreal bevacizumab provides improvement in visual acuity and reduction of macular edema in a high percentage of treated eyes after 1 year, even with low number of injections. Keywords: macular edema, retinal vein occlusion, bevacizumab, intravitreal injectionhttps://www.dovepress.com/the-outcome-of-low-frequency-intravitreal-bevacizumab-therapy-for-macu-peer-reviewed-article-OPTHmacular edemaretinal vein occlusionbevacizumabintravitreal injection |
| spellingShingle | Ivanovska Adjievska B Boskurt S Orovcanec N Dimovska-Jordanova V The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions Clinical Ophthalmology macular edema retinal vein occlusion bevacizumab intravitreal injection |
| title | The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions |
| title_full | The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions |
| title_fullStr | The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions |
| title_full_unstemmed | The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions |
| title_short | The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions |
| title_sort | outcome of low frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions |
| topic | macular edema retinal vein occlusion bevacizumab intravitreal injection |
| url | https://www.dovepress.com/the-outcome-of-low-frequency-intravitreal-bevacizumab-therapy-for-macu-peer-reviewed-article-OPTH |
| work_keys_str_mv | AT ivanovskaadjievskab theoutcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions AT boskurts theoutcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions AT orovcanecn theoutcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions AT dimovskajordanovav theoutcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions AT ivanovskaadjievskab outcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions AT boskurts outcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions AT orovcanecn outcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions AT dimovskajordanovav outcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions |